Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 10612027 Modified double-stranded RNA agents

Patent 10612027 was granted and assigned to Alnylam Pharmaceuticals on April, 2020 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Alnylam Pharmaceuticals

Current Assignee

Alnylam Pharmaceuticals

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

10612027

Date of Patent

April 7, 2020

Patent Application Number

16384644

Date Filed

April 15, 2019

Patent Citations Received

‌

US Patent 12071485 Compositions and methods of treating facioscapulohumeral muscular dystrophy

‌

US Patent 12104156 Compositions and methods of treating facioscapulohumeral muscular dystrophy

‌

US Patent 12084656 Products and compositions

‌

US Patent 11015198 Products and compositions

‌

US Patent 11912779 Compositions and methods of treating facioscapulohumeral muscular dystrophy

‌

US Patent 11999955 Compositions and methods of treating facioscapulohumeral muscular dystrophy

Patent Primary Examiner

‌

Amy H Bowman

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10612027 Modified double-stranded RNA agents

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API